MAX
Company Analysis ARS Pharmaceuticals, Inc.
1. Summary
Advantages
- Current debt level 0.012% is below 100% and has decreased over 5 years from 37.88%.
Disadvantages
- Price (9.34 $) is higher than fair price (1.56 $)
- Dividends (0%) are below the sector average (0.55%).
- The stock's return over the last year (-34.87%) is lower than the sector average (0.6%).
- The company's current efficiency (ROE=3.28%) is lower than the sector average (ROE=104.5%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| ARS Pharmaceuticals, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 3.8% | 9.6% | -1.5% |
| 90 days | -18.6% | -9.5% | 0.7% |
| 1 year | -34.9% | 0.6% | 13.2% |
SPRY vs Sector: ARS Pharmaceuticals, Inc. has significantly underperformed the "Healthcare" sector by -35.47% over the past year.
SPRY vs Market: ARS Pharmaceuticals, Inc. has significantly underperformed the market by -48.06% over the past year.
Stable price: SPRY is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: SPRY with weekly volatility of -0.67% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (9.34 $) is higher than the fair price (1.56 $).
Price is higher than fair: The current price (9.34 $) is 83.3% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (135.06) is higher than that of the sector as a whole (33.29).
P/E vs Market: The company's P/E (135.06) is higher than that of the market as a whole (-87.32).
5.2.1 P/E Similar companies
5.3. P/BV
P/BV vs Sector: The company's P/BV (4.21) is lower than that of the sector as a whole (249.13).
P/BV vs Market: The company's P/BV (4.21) is lower than that of the market as a whole (83.29).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (12.12) is lower than that of the sector as a whole (129.32).
P/S vs Market: The company's P/S indicator (12.12) is lower than that of the market as a whole (115.2).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-358.07) is lower than that of the sector as a whole (-27.64).
EV/Ebitda vs Market: The company's EV/Ebitda (-358.07) is lower than that of the market as a whole (-92.19).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -27.62% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-27.62%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (241.72%).
6.4. ROE
ROE vs Sector: The company's ROE (3.28%) is lower than that of the sector as a whole (104.5%).
ROE vs Market: The company's ROE (3.28%) is higher than that of the market as a whole (-6.66%).
6.6. ROA
ROA vs Sector: The company's ROA (2.74%) is higher than that of the sector as a whole (-2.18%).
ROA vs Market: The company's ROA (2.74%) is lower than that of the market as a whole (37.94%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (1.04%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.35%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.55%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
